Monday, February 24, 2020
Crispr technology has been around for several years. Essentially, Crispr is a “cut-and-paste” tool used in gene editing – especially useful when scientists have pinpointed specific disease-causing genes.
Fast forward to a very small study (3 people) released this week from the University of Pennsylvania and Stanford research teams that has cleared the first hurdle related to safety.
These cancer patients received their own genetically modified T cells – to make them more powerful hunters and killers of cancer cells. The T-cells were bathed in a special growing solution until they had increased to about a 100 million at which time they were infused back into the patient. The biggest concern was that once these cells were released back into the body, would they be too hyper-active, that is, trigger a massive deadly immune response. Instead, these gene edited immune cells lived and appeared to fit right back into the body’s immune system.
Results have been mixed: of the three patients, one woman with multiple myeloma died seven months after receiving the treatment and the other two, another with multiple myeloma and a man with sarcoma, have had their cancers return. A few other trials are getting underway. Overall, this promises to be an invaluable tool perhaps used in conjunction with other therapies.
To read more about this particular research, follow this link.
To read more about Crispr technology, read this article.
Friday, February 21, 2020
The seminar is FREE to women and their caregivers and includes lunch.
The topics, presented by the gyn/onc doctors from MGH - who I can't speak highly enough about - cover biology, surgery, personalized medicine, immunotherapy, advances in management of disease recurrence/clinical trials and other relevant and interesting topics.
Of course, there will also be time for Q&A. Parking is only $5 for all attendees with validation.
To register for this free event, follow this link.
Monday, February 17, 2020
What makes this website unique are the sidebars associated with each section providing informational links. For example, one link connects to a new page explaining why some genetic conditions are found more often in particular ethnic groups. There were also over 20 additional links to further resources.
To find out more about this website, follow this link.
Monday, February 10, 2020
Endometriosis Appears to Have No Effect on Ovarian Cancer Outcomes, But More Research Needed, Study Says
Endometriosis does not seem to significantly affect ovarian cancer prognosis and survival in patients of reproductive age, a small study suggests.
Monday, February 3, 2020
Weekly dose-dense paclitaxel as a frontline treatment for patients with epithelial ovarian cancer was not found to significantly improve progression-free survival (PFS) compared to the standard 3-weekly chemotherapy, according to results from the ICON8 study published in .“
The results of the ICON8 trial show that it is feasible to deliver weekly dose-dense paclitaxel in combination with either 3-weekly or weekly carboplatin in the first-line treatment of high-risk ovarian cancer,” Andrew Clamp, PhD, of The Christie NHS Foundation Trust, and colleagues wrote. “However, neither of these regimens is associated with an improvement in survival outcomes compared with standard 3-weekly carboplatin–paclitaxel treatment in the predominantly European population treated on this trial.”